跳至主要内容
临床试验/NCT02403518
NCT02403518终止不适用

A Prospective, Multi-National, Post-Marketing Study of the Clinical Outcomes of Wireless Neuromodulation Via the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain

Curonix LLC2 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2016年10月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Curonix LLC
入组人数
45
试验地点
2
主要终点
Percentage of pain relief experienced in the area of pain identified at baseline compared to 12 months post full implant of the Freedom SCS system.

研究概览

简要总结

This study evaluates the Freedom SCS (spinal cord stimulation) System for the treatment of chronic back and leg pain. Patients who have been diagnosed with failed back surgery syndrome (FBSS) will receive a stimulator device for treatment of their pain.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Appropriate Freedom SCS candidate as affirmed by study investigator
  • Candidate has a stable spine not suitable for further surgery as confirmed by physician
  • 18 years of age or older (no upper age limit)
  • Diagnosis of failed back surgery syndrome (FBSS) characterized by chronic, intractable pain of the legs, back, or both legs and back
  • At least 6 months since last surgical procedure on the spine
  • Average score of 60mm or greater on a VAS scale (Scale of 0 to 100, where 0 equals no pain and 100 equals worst possible pain)
  • Pain duration of at least 6 months
  • Expected lifespan of at least two years
  • Able to comply with study requirements
  • Gives informed consent for study participation

排除标准

  • A consistent VAS score of 100 over the past 24 hours as established at Visit 1
  • A co-existing condition that could increase the risk of SCS implantation (e.g., severe cardiac or respiratory disorders, coagulation disorder) or planned surgery within the study duration that could be compromised by SCS (e.g., diathermy)
  • Pregnant or planning to become pregnant
  • Known or suspected substance abuse within the last 2 years
  • Major psychiatric disorder (untreated or refractory to treatment) in the investigators opinion
  • Cognitive and/or behavioral issues that could impair study participation, (e.g., unreliability; defective memory; noncompliance in taking medications or keeping appointments; or impaired orientation to time, place, and events)
  • Documented allergy to Freedom SCS material components
  • Co-existing pain condition or participation in another clinical study that could confound the results of this study
  • History of another implanted medical device (e.g., explanted spinal cord stimulator, peripheral nerve stimulation, sacral nerve stimulator, pacemaker, or intrathecal drug delivery)

结局指标

主要结局

Percentage of pain relief experienced in the area of pain identified at baseline compared to 12 months post full implant of the Freedom SCS system.

时间窗: 12 months

Self reported pain intensity measured by the Visual Analog Scale (VAS)

Incidence and severity of device related adverse events during the study.

时间窗: Up to 12 months

次要结局

  • Improved quality of life function via the ODI and EQ-5D questionnaires(12 Months)
  • To assess compliance data to indicate usability of the device.(12 Months)
  • To assess the implanters' experience with the device.(Average of 7 days after implant)
  • Patient satisfaction with treatment.(12 Months)
  • Improved work status.(12 Months)
  • Reduced skin to skin time(Average of 7 days after implant)
  • To monitor non-device and non-SCS-related adverse events(Up to 12 months)
  • Reduced visits to health care institutes for chronic back and leg pain.(12 Months)
  • Reduction in use of analgesics(12 Months)
  • Reduced operating theater time(Average of 7 days after implant)
  • Reduced skin to fluoroscope time(Average of 7 days after implant)

研究者

发起方
Curonix LLC
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验